You just read:

Sorrento's TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies

News provided by

Sorrento Therapeutics, Inc.

Dec 01, 2016, 07:26 ET